Ms. Lewis currently serves as Executive Vice President, Chief Regulatory Strategy and Strategic Operations Officer at Karyopharm Therapeutics, a publicly-traded biopharmaceutical company (Nasdaq: KPTI). Ms. Lewis has a career that spans more than 20 years in drug development. She has held leadership positions at several companies, including Tesaro and Millennium. Tanya has deep experience negotiating approvals with both FDA and EMA. Her past accomplishments include the successful negotiations for registration trial designs and /or approval of VELCADE®, INTEGRILIN®, VARUBI®, ZEJULA® and XPOVIO®. Tanya holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Public Health from Massachusetts College of Pharmacy and Allied Health Science.